BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 34048168)

  • 1. Risk Factors of Daunorubicine Induced Early Cardiotoxicity in Childhood Acute Lymphoblastic Leukemia: A Retrospective Study.
    Samosir SM; Utamayasa IKA; Andarsini MR; Rahman MA; Ontoseno T; Hidayat T; Ugrasena IDG; Larasati MCS; Cahyadi A
    Asian Pac J Cancer Prev; 2021 May; 22(5):1407-1412. PubMed ID: 34048168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity.
    Sorensen K; Levitt G; Bull C; Chessells J; Sullivan I
    J Clin Oncol; 1997 Jan; 15(1):61-8. PubMed ID: 8996125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia.
    Nysom K; Holm K; Lipsitz SR; Mone SM; Colan SD; Orav EJ; Sallan SE; Olsen JH; Hertz H; Jacobsen JR; Lipshultz SE
    J Clin Oncol; 1998 Feb; 16(2):545-50. PubMed ID: 9469339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does anthracycline administration by infusion in children affect late cardiotoxicity?
    Levitt GA; Dorup I; Sorensen K; Sullivan I
    Br J Haematol; 2004 Feb; 124(4):463-8. PubMed ID: 14984495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of biomarkers and echocardiography in the evaluation of cardiotoxicity risk in children treated for leukemia.
    Raluca Maniu D; Blag C; Popa G; Bota M; Vlad C; Cainap C; Balacescu O; Pop L; Cainap SS
    J BUON; 2018 Dec; 23(7):122-131. PubMed ID: 30722121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Late cardiotoxicity after low dose of anthracycline therapy for acute lymphoblastic leukemia in childhood.
    Vandecruys E; Mondelaers V; De Wolf D; Benoit Y; Suys B
    J Cancer Surviv; 2012 Mar; 6(1):95-101. PubMed ID: 21630046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early-onset Cardiotoxicity assessment related to anthracycline in children with leukemia. A Prospective Study.
    Linares Ballesteros A; Sanguino Lobo R; Villada Valencia JC; Arévalo Leal O; Plazas Hernández DC; Aponte Barrios N; Perdomo Ramírez I
    Colomb Med (Cali); 2021 Feb; 52(1):e2034542. PubMed ID: 33911320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anthracycline-induced cardiotoxicity in patients with paediatric bone sarcoma and soft tissue sarcoma.
    Bini I; Asaftei SD; Riggi C; Tirtei E; Manicone R; Biasin E; Basso ME; Agnoletti G; Fagioli F
    Cardiol Young; 2017 Nov; 27(9):1815-1822. PubMed ID: 28780919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study.
    Sorensen K; Levitt GA; Bull C; Dorup I; Sullivan ID
    Cancer; 2003 Apr; 97(8):1991-8. PubMed ID: 12673729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two-dimensional speckle-tracking strain detects subclinical cardiotoxicity in older patients treated for acute myeloid leukemia.
    Cascino GJ; Voss WB; Canaani J; Furiasse N; Rademaker A; Ky B; Luger S; Altman JK; Foran JM; Litzow MR; Tallman MS; Rigolin V; Akhter N
    Echocardiography; 2019 Nov; 36(11):2033-2040. PubMed ID: 31705570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of ACE inhibitors in anthracycline-induced cardiotoxicity: A randomized, double-blind, placebo-controlled trial.
    Gupta V; Kumar Singh S; Agrawal V; Bali Singh T
    Pediatr Blood Cancer; 2018 Nov; 65(11):e27308. PubMed ID: 30009543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset Cardiotoxicity.
    Feijen EAM; Leisenring WM; Stratton KL; Ness KK; van der Pal HJH; van Dalen EC; Armstrong GT; Aune GJ; Green DM; Hudson MM; Loonen J; Oeffinger KC; Robison LL; Yasui Y; Kremer LCM; Chow EJ
    JAMA Oncol; 2019 Jun; 5(6):864-871. PubMed ID: 30703192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of echocardiography versus cardiac troponin I levels in the early detection of anthracycline cardiotoxicity in childhood acute leukemia: prospective evaluation of a 7-year-long clinical follow-up.
    Oztarhan K; Guler S; Aktas B; Arslan M; Salcioglu Z; Aydogan G
    Pediatr Hematol Oncol; 2011 Aug; 28(5):380-94. PubMed ID: 21699467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Noninvasive evaluation of chronic cumulative and acute cardiotoxicity induced by anthracycline in children with acute leukemia. Assessment of mainly left ventricular contractile state by M mode echocardiography].
    Nakada S; Ogawa S; Hirayama T
    Nihon Ika Daigaku Zasshi; 1994 Jun; 61(3):209-19. PubMed ID: 8045995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience.
    Krischer JP; Epstein S; Cuthbertson DD; Goorin AM; Epstein ML; Lipshultz SE
    J Clin Oncol; 1997 Apr; 15(4):1544-52. PubMed ID: 9193351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: a report from the Children's Cancer Group.
    Feig SA; Ames MM; Sather HN; Steinherz L; Reid JM; Trigg M; Pendergrass TW; Warkentin P; Gerber M; Leonard M; Bleyer WA; Harris RE
    Med Pediatr Oncol; 1996 Dec; 27(6):505-14. PubMed ID: 8888809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subclinical anthracycline-induced cardiotoxicity in long-term follow-up of asymptomatic childhood cancer survivors: Assessment by speckle tracking echocardiography.
    Çetin S; Babaoğlu K; Başar EZ; Deveci M; Çorapçıoğlu F
    Echocardiography; 2018 Feb; 35(2):234-240. PubMed ID: 29106752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exposure to anthracyclines during childhood causes cardiac injury.
    Lipshultz SE
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma.
    Sági JC; Egyed B; Kelemen A; Kutszegi N; Hegyi M; Gézsi A; Herlitschke MA; Rzepiel A; Fodor LE; Ottóffy G; Kovács GT; Erdélyi DJ; Szalai C; Semsei ÁF
    BMC Cancer; 2018 Jul; 18(1):704. PubMed ID: 29970035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose daunorubicin in induction treatment of childhood acute lymphoblastic leukemia: no long-term cardiac damage in a randomized study of the Dutch Childhood Leukemia Study Group.
    Rammeloo LA; Postma A; Sobotka-Plojhar MA; Bink-Boelkens MT; Berg A; Veerman AJ; Kamps WA
    Med Pediatr Oncol; 2000 Jul; 35(1):13-9. PubMed ID: 10881002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.